ESTRO 2024 - Abstract Book

S2562

Clinical - Urology

ESTRO 2024

2669

Digital Poster

Photon vs Proton Hypofractionation in Prostate Cancer: a systematic review and meta-analysis

Giulia Corrao 1 , Giulia Marvaso 1 , Federico Mastroleo 1,2 , Annalisa Biffi 3 , Giacomo Pellegrini 3 , Samuele Minari 3 , Maria Giulia Vincini 1 , Mattia Zaffaroni 1 , Dario Zerini 1 , Stefania Volpe 1,4 , Simona Gaito 5,6 , Giovanni Carlo Mazzola 1 , Luca Bergamaschi 1 , Federica Cattani 7 , Giuseppe Petralia 8,4 , Gennaro Musi 9,4 , Francesco Ceci 10,4 , Ottavio De Cobelli 9,4 , Roberto Orecchia 11 , Daniela Alterio 1 , Barbara Alicja Jereczek-Fossa 1,4 1 European Institute of Oncology IRCCS, Division of Radiation Oncology, Milan, Italy. 2 University of Piemonte Orientale (UPO), Department of Translational Medicine,, Novara, Italy. 3 University of Milano-Bicocca, National Centre of Healthcare Research and Pharmacoepidemiology, Milan, Italy. 4 University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy. 5 The Christie NHS Proton Beam Therapy Centre, Proton Clinical Outcomes Unit, Manchester, United Kingdom. 6 The University of Manchester, 4. Division of Clinical Cancer Science, School of Medical Sciences, Manchester, United Kingdom. 7 European Institute of Oncology IRCCS, Unit of Medical Physics, Milan, Italy. 8 IEO European Institute of Oncology IRCCS, Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, Milan, Italy. 9 European Institute of Oncology IRCCS, Division of Urology, Milan, Italy. 10 IEO European Institute of Oncology, IRCCS, Division of Nuclear Medicine and Theranostics, Milan, Italy. 11 European Institute of Oncology IRCCS, Scientific Directorate, Milan, Italy

Purpose/Objective:

- In recent years, the curative treatment of PCa with photon therapy (XRT) has shifted towards more hypofractionated treatments, with higher doses in a lower number of fractions. High-level evidence on hypofractionated proton therapy (PT) for localized and locally advanced prostate cancer (PCa) patients is currently missing. Aim of this study is to provide a systematic literature review to compare toxicity and effectiveness of curative RT with photons (XRT) or PT in PCa.

Material/Methods:

PubMed, Embase, and the Cochrane Library databases were systematically searched up to April 2022. Men with diagnosis of PCa who underwent to curative hypofractionated RT treatment (PT or XRT) were included. Risk of grade (G) ≥2 acute and late genitourinary (GU) and gastrointestinal (GI) toxicity were the primary outcomes of interest. Secondary outcomes were five-year biochemical relapse free survival (b-RFS), clinical relapse free, distant metastasis free, prostate cancer specific and overall survival (OS). Observational cohort studies investigating the occurrence of at least one of the considered outcomes among PCa patients underwent to either PT or XRT, as well as those investigating both patients who received PT and those who received XRT, were eligible for inclusion. Conference proceedings, guidelines, dissertations, commentaries, and letters as well as studies that used 2D/3D techniques and/or normofractionated treatments (≤ 2 Gy/fr) and those that did not report data on fractionation schedules and/or treatment settings were excluded from the present analysis..